LRI Investments LLC Grows Position in Natera, Inc. $NTRA

LRI Investments LLC boosted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 469.3% during the 2nd quarter, Holdings Channel.com reports. The firm owned 501 shares of the medical research company’s stock after buying an additional 413 shares during the quarter. LRI Investments LLC’s holdings in Natera were worth $85,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Guided Capital Wealth Management LLC raised its holdings in Natera by 0.5% during the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock valued at $2,219,000 after acquiring an additional 66 shares during the period. Wedmont Private Capital raised its holdings in Natera by 4.9% during the second quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock valued at $256,000 after acquiring an additional 74 shares during the period. Compound Planning Inc. raised its holdings in Natera by 4.2% during the first quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company’s stock valued at $271,000 after acquiring an additional 78 shares during the period. QRG Capital Management Inc. raised its holdings in Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company’s stock valued at $766,000 after acquiring an additional 81 shares during the period. Finally, Earned Wealth Advisors LLC raised its holdings in Natera by 5.0% during the first quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 82 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Trading Up 2.9%

Shares of NTRA stock opened at $174.17 on Tuesday. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $183.00. The stock’s 50-day moving average price is $165.33 and its 200-day moving average price is $157.54. The stock has a market capitalization of $23.90 billion, a price-to-earnings ratio of -91.19 and a beta of 1.74.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same period in the previous year, the firm earned ($0.30) earnings per share. The company’s revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Activity at Natera

In other Natera news, CFO Michael Burkes Brophy sold 2,491 shares of the business’s stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $162.05, for a total transaction of $403,666.55. Following the sale, the chief financial officer directly owned 69,189 shares of the company’s stock, valued at $11,212,077.45. The trade was a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Rowan E. Chapman sold 2,750 shares of the business’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the sale, the director directly owned 6,015 shares in the company, valued at $1,004,444.85. The trade was a 31.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,464 shares of company stock valued at $10,963,125 over the last ninety days. 5.63% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent analyst reports. Cowen reissued a “buy” rating on shares of Natera in a report on Friday, August 8th. Evercore ISI raised Natera to a “strong-buy” rating and set a $170.00 price target on the stock in a report on Monday, July 28th. Morgan Stanley reissued an “overweight” rating and set a $195.00 price target on shares of Natera in a report on Sunday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada set a $268.00 target price on Natera and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $192.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.